TROP2-Targeted ADC Demonstrates Significant PFS Improvement in Breast and Lung Cancers; Amgen’s KRAS Inhibitor Combo Reduces Colorectal Cancer Progression Risk by 51%

▎WuXi

Edited by Kant Content Team

Today, all abstracts from the European Society for Medical Oncology (ESMO) conference are available online.The European Society for Medical Oncology (ESMO) Congress is one of the most influential oncology conferences globally.The 2023 ESMO Congress will be held from October 20 to 24 in Madrid, Spain. This article will introduce some of the highly anticipated major studies to be presented at the ESMO Congress.

Multiple Phase 3 clinical results of datopotamab deruxtecan (Dato-DXd), a Trop2-targeted antibody-drug conjugate jointly developed by AstraZeneca and Daiichi Sankyo, will be announced at the conference. According to the abstract,Dato-DXd Meets Primary Endpoint in Phase 3 Clinical Trial TROPION-Breast01 for Unresectable or Metastatic HR+/HER2- Breast Cancer Patients Who Have Undergone Multiple Prior Treatments. As of July 17, 2023,Dato-DXd significantly improved progression-free survival (PFS) compared to investigator-selected chemotherapy, reducing the risk of disease progression by 37% (HR=0.63, 95% CI: 0.52-0.76, p

Overall Survival (OS) data are not yet mature, but Dato-DXd shows a favorable trend. See the table below for specific data.

Image Source: ESMO Official Website

In the phase 3 clinical trial for previously treated advanced or metastatic non-small cell lung cancer (NSCLC) patients, PFS was significantly improved in the Dato-DXd group compared to paclitaxel. The PFS for Dato-DXd was 4.4 months, while the control group had a PFS of 3.7 months.For specific data, please see the table below.

Image Source: ESMO Official Website

Novartis will announce the Phase 3 trial results of Pluvicto, a radioactive ligand therapy targeting Prostate-Specific Membrane Antigen (PSMA), for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) prior to receiving taxane chemotherapy at the conference. The abstract shows that, at the time of the primary analysis,Pluvicto (177Lu-PSMA-617) met the primary endpoint of radiographic progression-free survival (rPFS) (HR=0.41, 95% CI: 0.29-0.56; p

. For the detailed data of the second interim analysis, please refer to the table below.

Image Source: ESMO Official Website

Amgen will announce the results of a phase 3 clinical trial combining the KRAS G12C inhibitor sotorasib with the EGFR antibody panitumumab for the treatment of patients with chemotherapy-resistant metastatic colorectal cancer who carry the KRAS G12C mutation. The abstract indicates that this trial met its primary endpoint.Different doses of the sotorasib/panitumumab combination significantly improved progression-free survival compared to standard treatment.Daily960 mg dose group of sotorasibReduce the risk of disease progression by 51%(HR=0.49, 95% CI: 0.30-0.80; p=0.006). Daily240 mg Sotorasib Dose Reduces Risk of Disease Progression by 42%(HR=0.58, 95% CI: 0.36-0.93; p=0.03). Survival data are not yet mature. See the table below for specific data.

Image Source: ESMO Official Website

Bristol-Myers Squibb to Announce Its Key PD-1 InhibitorPhase 3 Clinical Trial Results of Nivolumab in Combination with Chemotherapy as Neoadjuvant Therapy and as Monotherapy for Adjuvant Therapy after Surgery in Patients with Resectable Stage II-IIIb Non-Small Cell Lung Cancer.The abstract shows that the nivolumab-based treatment regimen significantly improved patients' event-free survival (EFS) compared to chemotherapy as a neoadjuvant therapy and placebo as an adjuvant therapy.The median EFS in the nivolumab group has not yet been reached, compared to 18.4 months in the control group (HR=0.58, 97.36% CI: 0.42-0.81, p=0.00025). The nivolumab group also showed an improved pathological complete response rate (25.3% vs. 4.7%).

Johnson & Johnson will announce the Phase 3 clinical trial results of amivantamab, a bispecific therapy targeting EGFR/MET, in combination with lazertinib, an oral tyrosine kinase inhibitor, as a first-line treatment for patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer. The abstract reveals that in the MARIPOSA clinical trial,The combination of amivantamab/lazertinib significantly improved progression-free survival in patients compared to the active control group, reducing the risk of disease progression or death by 30% (HR=0.70, 95% CI: 0.58-0.85; p

Interim OS data show a favorable trend for the amivantamab/lazertinib group.